A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

• Status: Terminated
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia) and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia)

• Patients must have adequate organ function

• Patients must have documented T315I mutation

Exclusion Criteria:

• Patients within 3 months of allogeneic bone marrow transplant or not fully recovered from previous anti-leukemia therapy

• Patients with uncontrolled congestive heart failure

• Patients with active or uncontrolled infection or active Hepatitis B or C

• Patients with known HIV positivity or AIDS related illness

• Patients with currently active second malignancy, other than non-melanoma skin cancer.